Neoadjuvant chemotherapy (NACT) is being increasingly used as the frontline therapy for the management of high-risk, locally advanced, or unresectable breast cancers. The main objective of NACT has long been to obtain the downstaging of the neoplasm, increasing the number of women eligible for breast conservation surgery.
Early identification of patients who are responders or non-responders would be beneficial to improve and personalize treatment planning thus sparing patients from potentially ineffective and/or toxic treatment. Moreover, the achievement of pathological Complete Response may be considered as an independent predictor of better disease-free survival. The care of Breast Cancer patients has changed considerably over the last few decades, integrating NACT into the multidisciplinary management of many neoplasms. Within this emerging scenario, the role of imaging as an indispensable assessment tool for monitoring the response to therapy is a hot topic in the scientific community.
We welcome original research, cutting-edge reviews, and clinical studies related but not limited to the following:
- Identification and validation of new clinically significant biomarkers for the early prediction of response to neoadjuvant therapy and the prognosis of breast cancer;
- Analysis and validation of data identifying new features of breast cancer to guide and monitor neoadjuvant treatment;
- Prediction models based on radiomic analysis of images using artificial intelligence techniques;
- Identification of drug targets in breast cancer and classified subgroups;
- Clinical studies illustrating the response to neoadjuvant therapy in breast cancer
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Neoadjuvant chemotherapy (NACT) is being increasingly used as the frontline therapy for the management of high-risk, locally advanced, or unresectable breast cancers. The main objective of NACT has long been to obtain the downstaging of the neoplasm, increasing the number of women eligible for breast conservation surgery.
Early identification of patients who are responders or non-responders would be beneficial to improve and personalize treatment planning thus sparing patients from potentially ineffective and/or toxic treatment. Moreover, the achievement of pathological Complete Response may be considered as an independent predictor of better disease-free survival. The care of Breast Cancer patients has changed considerably over the last few decades, integrating NACT into the multidisciplinary management of many neoplasms. Within this emerging scenario, the role of imaging as an indispensable assessment tool for monitoring the response to therapy is a hot topic in the scientific community.
We welcome original research, cutting-edge reviews, and clinical studies related but not limited to the following:
- Identification and validation of new clinically significant biomarkers for the early prediction of response to neoadjuvant therapy and the prognosis of breast cancer;
- Analysis and validation of data identifying new features of breast cancer to guide and monitor neoadjuvant treatment;
- Prediction models based on radiomic analysis of images using artificial intelligence techniques;
- Identification of drug targets in breast cancer and classified subgroups;
- Clinical studies illustrating the response to neoadjuvant therapy in breast cancer
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
